Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study.
| Autor: | Barr, Paul M., Allan, John N., Siddiqi, Tanya, Wierda, William G., Tam, Constantine Si Lun, Moreno, Carolina D., Tedeschi, Alessandra, Szafer-Glusman, Edith, Zhou, Cathy, Abbazio, Chris, Dean, James P., Szoke, Anita, Ghia, Paolo |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p7535-7535, 1p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|